Ocumension Therapeutics (HKSE:01477) EPS (Basic) : HK$-0.42 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics EPS (Basic)?

Ocumension Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was HK$-0.17. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.42.

Ocumension Therapeutics's EPS (Diluted) for the six months ended in Dec. 2024 was HK$-0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.42.

Ocumension Therapeutics's EPS without NRI for the six months ended in Dec. 2024 was HK$-0.17. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.42.

During the past 3 years, the average EPS without NRI Growth Rate was 19.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 38.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Ocumension Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 57.30% per year. The lowest was -23.90% per year. And the median was 26.90% per year.

Ocumension Therapeutics EPS (Basic) Historical Data

The historical data trend for Ocumension Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics EPS (Basic) Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-8.30

-0.53

-0.72

-0.65

-0.42

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial								-0.37	-0.35	-0.30	-0.25	-0.17

Ocumension Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Ocumension Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-286.429	-	0)	/	683.807
	=	-0.42

Ocumension Therapeutics's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-124.846	-	0)	/	708.412
	=	-0.18

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.42

Ocumension Therapeutics (HKSE:01477) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ocumension Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

https://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Liu Ye	2101 Beneficial owner
6 Dimensions Capital, L.p.	2101 Beneficial owner
Zhang Qiping	2201 Interest of corporation controlled by you
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Boyu Capital Fund Iv, L.p.	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
Alcon Pharmaceuticals Ltd	2101 Beneficial owner
Alcon Inc.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

Ocumension Therapeutics Headlines

No Headlines